Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.54 |
| ▸ | HINT1 | P49773 | 4/20 | 0.49 |
| ▸ | TYMP | P19971 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 2/20 | 0.44 |
| ▸ | ATG7 | O95352 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11421357 | 0.87 | POLB (0.67) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL6914202 | 0.84 | KDM4E (0.57) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL29390156 | 0.84 | PNP (0.64) | PNPNT5EATG7 | |
| SCHEMBL22498807 | 0.84 | PNP (0.64) | PNPNT5EATG7 | |
| SCHEMBL16359949 | 0.84 | POLB (0.70) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL338650 | 0.84 | POLB (0.70) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL8490891 | 0.83 | POLB (0.71) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL442294 | 0.83 | POLB (0.71) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL766552 | 0.83 | ENPP1 (0.60) | POLBATG7 | |
| SCHEMBL2788058 | 0.83 | ENPP1 (0.60) | POLBATG7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1097939-B1 | Method for the synthesis of isoguanosine and of its 2'-derivatives | BAYER AG (US) | 2004-02-11 | — | — | EP | disclosed |
| EP-0778898-B1 | REDUCTION OF NONSPECIFIC HYBRIDIZATION BY USING NOVEL BASE-PAIRING SCHEMES | BAYER AG (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20010026918-A1 | Reduction of nonspecific hybridization by using novel base-pairing schemes | COLLINS MARK L (US) | 2001-10-04 | — | — | US | disclosed |
| US-6232462-B1 | SYNTHESIS OF AN ISOGUANOSINE DERIVATIVE USED AS ANTISENSE AND APTAMER THERAPEUTICS AND DRUG DISCOVERY | BAYER CORPORATION | 2001-05-15 | — | — | US | disclosed |
| EP-1097939-A2 | Method for the synthesis of isoguanosine and its 2'-derivatives | Bayer Corporation (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-0778898-A1 | REDUCTION OF NONSPECIFIC HYBRIDIZATION BY USING NOVEL BASE-PAIRING SCHEMES | CHIRON CORPORATION (US) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996006950-A9 | REDUCTION OF NONSPECIFIC HYBRIDIZATION BY USING NOVEL BASE-PAIRING SCHEMES | — | 1997-05-09 | — | — | WO | disclosed |
| WO-1996006950-A1 | REDUCTION OF NONSPECIFIC HYBRIDIZATION BY USING NOVEL BASE-PAIRING SCHEMES | CHIRON CORPORATION (US) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010026918-A1 | Reduction of nonspecific hybridization by using novel base-pairing schemes | UNG, SAMHD1, RNGTT | POLB 46/4885P2RY2 1436/4885P2RY4 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.